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Expression of the vault RNA protects cells from
undergoing apoptosis
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Non-protein-coding RNAs are a functionally versatile class of transcripts exerting their
biological roles on the RNA level. Recently, we demonstrated that the vault complex-
associated RNAs (vtRNAs) are signiﬁcantly upregulated in Epstein–Barr virus (EBV)-infected
human B cells. Very little is known about the function(s) of the vtRNAs or the vault complex.
Here, we individually express latent EBV-encoded proteins in B cells and identify the latent
membrane protein 1 (LMP1) as trigger for vtRNA upregulation. Ectopic expression of vtRNA1-
1, but not of the other vtRNA paralogues, results in an improved viral establishment and
reduced apoptosis, a function located in the central domain of vtRNA1-1. Knockdown of the
major vault protein has no effect on these phenotypes revealing that vtRNA1-1 and not the
vault complex contributes to general cell death resistance. This study describes a NF-kB-
mediated role of the non-coding vtRNA1-1 in inhibiting both the extrinsic and intrinsic
apoptotic pathways.
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N
on-protein-coding RNAs (ncRNAs) function on the level
of RNA and are not translated into proteins. ncRNAs
are prevalent in regulating many important cellular
processes in all domains of life1. Initially, ncRNAs were
suggested to only play functional roles in protein synthesis as
integral components (ribosomal RNA) or reaction substrates
(transfer RNA) of the ribosome but over the years multiple
additional functions were identiﬁed. They are involved in
regulating a diversity of fundamental processes including
transcription, translation, RNA processing, mRNA turnover,
DNA replication, genome stability, chromatin remodelling
and even contribute to the stability and location of proteins1–5.
Due to the power of deep-sequencing methods, more
comprehensive insights into cellular transcriptomes became
possible and emphasized that multicellular eukaryal organisms
possess signiﬁcantly more ncRNA genes compared with more
primitive single-cell eukaryotes (for example, yeast) or
prokaryotes. These results led to the hypothesis, that ncRNAs
can establish intricate regulatory networks and may be key to
understanding the increased complexity of mammals compared
with ‘lower organisms’, despite the only modestly higher number
of protein-coding genes6.
However, many of the cellular ncRNA transcripts lack
experimental conﬁrmation of their biological role. Even though
the class of vault RNAs (vtRNAs) have been initially identiﬁed
almost 30 years ago7, its function is not yet completely clear. The
vtRNAs have been identiﬁed as integral components of the vault
complex, a hollow barrel-shaped ribonucleoprotein (RNP)
complex with a size of 13MDa found in most eukaryotes8.
This gigantic complex is by far the largest cellular RNP identiﬁed
to date and several functions have been suggested for the
vault complex. These include roles in nucleocytoplasmic
transport9, intracellular detoxiﬁcation processes and hence in
multidrug resistance of cancer cells10,11, signalling12,13, apoptosis
resistance14, innate immune response15, DNA damage repair16
and recently also in nuclear pore complex formation17. In
addition to the vtRNAs, the vault complex consists of multiple
copies of three proteins: the major vault protein (MVP), the
vault poly(ADP-ribose)-polymerase (vPARP) and the telomerase-
associated protein 1 (TEP1). MVP is the major structural protein
of the vault complex, contributes with B70% to the particles
mass and self-assembles to form vault-like particles in vivo18. In
humans, four vtRNA paralogues, vtRNA1-1, vtRNA1-2, vtRNA1-
3 and vtRNA2-1, have been detected8,19. They are 88–100
nucleotides in length, are clustered on chromosome 5, and show
little sequence conservation between species except their A and B
boxes, which are internal polymerase III elements. The
stoichiometric model of the vault particle proposes that it
contains at least six copies of vtRNA which, however,
comprise o5% of the total vault complex mass. Intriguingly,
only 5% of the vtRNAs are directly associated to the vault
particle, whereas the remaining 95% are evenly distributed
throughout the cytoplasm10,19,20. In addition, minute nuclear
vtRNA localization has been reported as well21.
Recently, we observed that vtRNAs were upregulated in human
B cells upon Epstein–Barr virus (EBV) infection19,22. EBV
belongs to the g-herpesvirus family and is involved in
the development of aggressive lymphomas and carcinomas,
such as Burkitt lymphoma (BL), Hodgkins lymphoma and
nasopharyngeal carcinoma23. Three main types of EBV latency
stages are known (latency I–III), which are characterized by the
expression of a distinct set of viral genes depending on the
infected cell type24. In vitro infection of the EBV-negative
lymphoid cell line BL2 establishes a latency III pattern,
characterized by the expression of nine EBV proteins (EBNA1,
EBNA2, EBNA3a, 3b, 3c, EBNA-LP, LMP1, LMP2a and LMP2b),
two ncRNAs (EBER1 and EBER2) and several miRNAs (BART
and BHRFs)25,26. Hence, there seems to be a causal link between
the presence of EBV and the upregulation of cellular vtRNAs19.
In this work, we individually overexpress most latent
EBV-encoded proteins and identify LMP1 as trigger for
NF-kB-dependent vtRNA1-1 expression. Ectopic expression of
vtRNA1-1 in a B-cell line that usually lacks this ncRNA renders
the cells amenable to efﬁcient EBV infection by protecting them
from undergoing apoptosis. Knockdown experiments of the MVP
reveals that the anti-apoptotic effect is a function of vtRNA1-1
not associated with the genuine vault complex. While the MVP
has been previously suggested to inhibit apoptosis in senescent
cells14, this study is the ﬁrst report demonstrating general
apoptotic resistance upon vtRNA1-1 expression in malignant B
cells.
Results
LMP1 stimulates vtRNA1-1 expression in BL2 cells. Previously,
we have shown that EBV infection of Burkitt lymphoma BL2
or BL41 cells leads to a signiﬁcant upregulation of human
vtRNA1-1 and vtRNA2-1, or vtRNA2-1, respectively19,22. To
determine which EBV-encoded gene product triggers this
host cell response, we individually overexpressed latency
phase III proteins in BL2 cells25,26. By using stable lentiviral
transduction, we successfully expressed the EBV proteins
EBNA1, EBNA2, EBNA-LP, LMP1, LMP2a and LMP2b in
these cells (Supplementary Fig. 1). The EBNA3-A, -B, -C family
was not included in this study since its function is predominately
transcriptionally repressive27,28. Subsequent to EBV-protein
expression the vtRNA levels were analysed by northern blot
analysis (Fig. 1a, Supplementary Fig. 2) and by quantitative
real-time PCR (Fig. 1b). These analyses revealed that only
LMP1 signiﬁcantly contributed to vtRNA1-1 upregulation (up to
6-fold), while the expression of the other EBV-encoded proteins
LMP2a, LMP2b, EBNA1, EBNA2 and EBNA-LP had little or no
effect (Fig. 1a,b). This effect is speciﬁc for vtRNA1-1 since no
upregulation of the other vtRNA paralogues was observed
(Supplementary Fig. 3a). This LMP1-dependent expression of
vtRNA1-1 was also evident in several other B cell lymphoma lines
(Supplementary Figs 3b and 4c,d). LMP1, a six-transmembrane
domain protein, is the principal EBV oncogene and is essential
for efﬁcient B-cell transformation29. It inﬂuences host gene
expression through the activation of different signalling pathways.
The cytoplasmic C-terminal activator regions (CTAR) 1 and 2
associate with cellular signaling molecules and stimulate the
following pathways: CTAR1 is involved in triggering the non-
canonical NF-kB pathway, the PI3K and the JAK/STAT
pathways, and the MAPK pathways ERK, p38 and in some
cell lines, JNK. CTAR2 is known for activating the canonical
NF-kB pathway and the MAPK pathways JNK and p38 (Fig. 1c).
To gain deeper insight into the LMP1-mediated vtRNA
upregulation, LMP1 mutants with individually inactivated
CTAR domains (M_CTAR1 representing a P204QT -
AAA mutation, or M_CTAR2 harbouring a deletion of the
C-terminal residues 371–386), or a variant carrying both CTAR
mutations simultaneously (M_CTAR1&2) were expressed in BL2
cells (Supplementary Fig. 1). Quantitative real-time PCR
demonstrated that both single CTAR mutants retained activities
in vtRNA1-1 upregulation, while the double mutant
(M_CTRAR1&2) has lost its potential to stimulate expression
of vtRNA1-1 (Fig. 1d). This activity proﬁle of the LMP1 mutants
is compatible with the notion that LMP1 activates vtRNA1-1
expression through both the canonical and the non-canonical
NF-kB pathways. In support of this interpretation, repeating the
experiment in the presence of the IKK-VII inhibitor at
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concentrations efﬁciently blocking IKK-a, central to both NF-kB
pathways, completely abolished vtRNA1-1 upregulation in LMP1
expressing BL2 cells (Fig. 1e). Consistent with LMP1-driven
NF-kB activation, the upregulation of three NF-kB target genes,
that is, Bcl-xL, IL6 and c-FLIP was observed (Supplementary
Fig. 3c). To determine a direct interaction of the dominant NF-kB
member p65/RelA with the vtRNA1-1 promoter, we performed
NF-kB chromatin immunoprecipitation (ChIP) experiments
(Fig. 1f). According to CHIP-seq data of the ENCODE project,
a NF-kB binding site was predicted within the promotor region of
vtRNA1-1 (refs 30, 31). Indeed, our ChIP experiments revealed a
signiﬁcant enrichment of the vault RNA1-1 promoter in LMP1-
overexpressing or EBV infected BL2 cells. We observed a minor
enrichment in the empty vector control, indicative for basal
promoter occupancy by p65/RelA under steady state conditions
(Supplementary Fig. 3d), suggesting that the weak endogenous
vtRNA1-1 levels in the parental BL2 cell line were also NF-kB-
dependent (Fig. 1a). In accordance with the ENCODE project, we
also did not observe any enrichment of the vtRNA1-2 promoter
region, highlighting the speciﬁcity of the ChIP assay (Fig. 1f). In
summary, these experiments provide evidence that NF-kB is
involved in regulating the vtRNA1-1 but not the vtRNA1-2
promoter.
Ectopic expression of vtRNA1-1 stimulates EBV establishment.
Our data suggest that LMP1 is the EBV-protein upregulating
vtRNA1-1 in BL2 cells. We next addressed the question whether
this host ncRNA has an impact on the EBV infection process. To
study the putative causal link between EBV infection and
vtRNA1-1 upregulation, we ectopically expressed vtRNAs in
human B cells and tested the consequences on EBV infection. For
these experiments, the BL41 cell line was used since EBV infec-
tion normally does not trigger detectable vtRNA1-1 levels in this
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Figure 1 | vtRNA levels in response to expression of EBV-encoded latency III proteins. (a) Northern blot analysis was used to assess the effects of
overexpressing EBV-encoded proteins on the vtRNA1-1 levels in different BL2 cell lines. The 5S rRNA serves as internal loading control. ( ) indicate
untreated BL2 cells, whereas EVC indicates the empty vector control. EBV strain B95.8 was used as positive infection control (þ EBV). The mean and
standard deviation of three different experiments are shown beneath the blot, whereas the vtRNA1-1 expression levels in untreated BL2 cells ( ) was taken
as 1.0. See also Supplementary Fig. 2. (b) Real-time qPCR was used to quantify vtRNA1-1 levels in the untreated BL2 control ( ) or in BL2 cells
overexpressing latency stage III proteins. Real-time qPCR data shown are the mean values from three individual assays; TBP served as housekeeping gene.
‘Fold induction’ was calculated using the comparative Dct method where BL2 served as calibrator. (c) Schematic representation of LMP1 domain
organization. The different signalling pathways controlled by the signalling modules CTAR1 and CTAR2 are indicated. (d) Real-time qPCR to investigate the
effect of LMP1 mutants (M_CTAR 1 and M_CTAR 2 carry detrimental amino-acid substitutions or a deletion in CTAR domains 1 or 2, respectively) on the
vtRNA1-1 level in BL2 cells. Data shown are the mean values and standard deviations of three independent assays. (e) In the presence of an NF-kB inhibitor
(inh.), northern blot analysis showed no LMP1-dependent upregulation of vtRNA1-1. 5.8 S rRNA serves as internal loading control. (f) ChIP efﬁciencies
using an NF-kB p65 antibody were monitored using qPCR on vtRNA1-1 and vtRNA1-2 promoter regions from BL2 cells carrying the empty vector (evc),
expressing LMP1 (þ LMP1), or from EBV-infected BL2 cells. Data shown are mean values and standard deviations from three individual assays. Signiﬁcant
differences relative to the mock control (no antibody) were determined using the two-tailed unpaired Student’s t-test (***Po0.001, **Po0.01, *Po0.01).
In b and d, signiﬁcant differences in fold induction relative to the untreated BL2 cells ( ) were determined using the two-tailed unpaired Student’s t-test
(***Po0.001, **Po0.01).
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cell line19. Thus the effects of ectopically expressed vtRNA1-1 on
EBV infection can be studied without any detectable endogenous
vtRNA background expression. Stably transfected BL41 cell
lines were established expressing vtRNA1-1 or the paralogues
vtRNA1-2 and vtRNA1-3 (Fig. 2a, Supplementary Fig. 5).
Subsequently, these cell lines were infected with the
recombinant GFP expressing EBV variant 2089 (ref. 32) and
the number of GFP-positive cells was determined by
ﬂuorescence-activated cell sorting analysis 72 h post infection.
The vtRNA1-1 overexpressing cell line showed a markedly
enhanced viral establishment rate (Fig. 2b). In fact, the empty
vector control cell line, which does not express detectable levels of
vtRNA1-1, was almost resistant to EBV infection (Fig. 2b). Cells
expressing the paralogue vtRNA1-2 behaved like the empty
vector control cells and were poorly infected by the virus
(Fig. 2b), thus hinting at a vtRNA1-1 speciﬁc effect. The
enhanced EBV establishment can be partly explained by the
fact that the vtRNA1-1 overexpressing cell line exhibited an
accelerated growth rate compared with the parental BL41 cell line
(Supplementary Fig. 4a). However, this phenotype was not linked
to an altered cell cycle proﬁle in the vtRNA1-1 overexpressing cell
line (Supplementary Fig. 4b). Furthermore, the enhanced virus
establishment likely originates from the decreased cell death rate
of the BL41 cells expressing vtRNA1-1 in the presence of EBV
(Fig. 2c).
vtRNA1-1 expression confers apoptosis resistance. To unravel
the reason for the observed increased EBV establishment in
vtRNA1-1 overexpressing cell lines, the fraction of apoptotic cells
in the culture was determined by Annexin V staining. Indeed,
expression of vtRNA1-1, but not vtRNA1-2, or vtRNA1-3,
protected BL41 cells from undergoing apoptosis after EBV infec-
tion (Fig. 2c). To examine the role of vtRNA1-1 in general
apoptosis resistance, we challenged the vtRNA overexpressing cell
lines with two well-known inducers of intrinsic programmed cell
death, namely the pan-kinase inhibitor staurosporine or the
topoisomerase-II inhibitor etoposide. Cells were treated for 24 h
with either drug and subsequently subjected to the Annexin
binding assay followed by ﬂow cytometric analysis. BL41 cells
overexpressing vtRNA1-1 exhibited a signiﬁcantly reduced apop-
tosis rate compared with the control cell line (Fig. 2d). Again,
expression of the paralogues vtRNA1-2 and vtRNA1-3 did not
protect BL41 cells from undergoing cell death. In addition, only
vtRNA1-1 protected BL41 cells from the Fas ligand-induced
extrinsic apoptosis (Fig. 2e). The vtRNA-mediated apoptosis
resistance was dosage dependent, since short hairpin RNA
(shRNA)-mediated knockdown of vtRNA1-1 expression in BL41
cells reversed the cell death resistance phenotype. Reducing the
vtRNA1-1 levels by about half resulted in a markedly increased
apoptosis (Fig. 3a,b, Supplementary Fig. 6). Dose dependency of
vtRNA1-1-triggered apoptosis resistance was also evident in BL2
cells (Supplementary Fig. 7). A similar effect was observed in HeLa
cells and in the breast cancer cell line HS578T in which the
endogenous vtRNA1-1 levels were reduced by B50% by an anti-
sense oligonucleotide (ASO) approach33. Knockdown of vtRNA1-1
levels in these two cancer cell lines resulted in a clear increase of
spontaneous cell death in culture (Fig. 3c–f). In both of these
cancer cell lines, vtRNA1-1 expression appears to be also driven by
NF-kB since the levels signiﬁcantly decreased in the presence of
the IKK inhibitor VII (Fig. 3g). Taken together, these ﬁndings
indicate that vtRNA1-1 has an important impact on apoptosis
resistance in different cancer cell types.
vtRNA1-1 central domain is responsible for apoptosis resistance.
The data described above showed that expression of vtRNA1-1 but
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Figure 2 | Effect of vtRNA levels on EBV infection and apoptosis. (a)
Northern blot analysis reveals the amount of ectopically expressed vtRNA1-1,
1-2 and 1-3 in BL41 cells. The 5.8S rRNA serves as internal loading control.
See also Supplementary Fig. 5. (b) Fluorescence-activated cell sorting (FACS)
analysis to investigate the effect of infecting the BL41 cell line with the
recombinant EBV virus 2089 (ref. 32) in the absence ( ) or presence of
ectopically expressed vtRNA1-1 or vtRNA1-2. The data shown represent the
mean and standard deviation of 11 independent experiments. The GFP-
positive (pos.) Raji cells after EBV infection (infection efﬁciency typically
30%) served as positive infection control and were taken as 1.0. (c) The
same cells as in b were labelled with annexin V PE and apoptotic cells were
recorded on FL-2. (d) BL41 cells without ( ) or with vtRNA1-1, 1-2 or 1-3
expression were treated with staurosporine (Stau) or etoposide (Eto) and the
amount of apoptotic cells was determined by FACS analysis after an annexin
stain. The data originates from ﬁve independent experiments. The number of
apoptotic cells in the untreated control was subtracted in each individual
experiment from the staurosporine- or etoposide-treated ones. The numbers
of apoptotic cells in the untreated controls were o12%. (e) BL41 cells
without ( ) or with vtRNA1-1 expression were treated with anti-Fas
antibody and the amount of apoptotic cells determined. The mean and
standard deviations of two independent experiments are shown. The
numbers of apoptotic cells in the untreated controls were o10% and were
subtracted from each experiment. In b, c, d and e, signiﬁcant differences
relative (rel.) to the untreated control cells ( ) were determined using the
two-tailed unpaired Student’s t-test (***Po0.001, **Po0.01).
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not of the vtRNA1-2 or vtRNA1-3 paralogues confer resistance to
apoptosis in different cell lines including BL41. The vtRNA
paralogues are highly similar and differ only slightly in primary and
secondary structure, especially in the terminal stem-loop region
(Fig. 4a). The main differences between vtRNAs paralogues reside
in the central domain8. To determine the speciﬁc sequence
motif(s) of vtRNA1-1 contributing to the anti-apoptotic effect,
vtRNA mutants were generated and expressed in BL41 cells
(Fig. 4a,b, Supplementary Fig. 8). Therefore those nucleotides in
vtRNA1-2 that differ from vtRNA1-1 in the terminal stem-loop
domain (M1–M3) were introduced into the latter. Furthermore,
the central domain of vtRNA1-2 was swapped into the
corresponding region of vtRNA1-1 (M4). Transduced cells
were treated with staurosporine for 24h and the fraction of
dead cells determined by Annexin V staining. It turned out that
none of the vtRNA1-1 variants carrying base changes in the
terminal stem-loop (M1–M3) has lost its principal ability to
protect cells from undergoing apoptosis (Fig. 4c). However,
swapping the central domain of vtRNA1-2 into the vtRNA1-1
molecule (M4) made BL41 cells again susceptible to the
staurosporine treatment and reduced the ability of this
transcript to protect cells from apoptosis (Fig. 4c). These
data indicate the central domain of vtRNA1-1 (from residues
22–75) as the major determinant for the anti-apoptotic effect. To
substantiate this interpretation, we constructed a ‘reverse-swap’
mutant (M5), in which the central domain of vtRNA1-1 was
transplanted into the non-protective vtRNA1-2 paralogue. Indeed,
expression of this chimeric vtRNA M5 protected cells from
undergoing apoptosis (Fig. 4c). Thus the anti-apoptotic
characteristics of vtRNA1-1 can be transplanted into the
vtRNA1-2 backbone by swapping the central domain conﬁrming
that this domain of vtRNA1-1 is essential and sufﬁcient to render
BL41 cells staurosporine resistant.
Apoptosis resistance is a function of the vtRNA. It has been
demonstrated previously that only B5% of cellular vtRNA
transcripts are actually associated with the vault complex while
the remaining 95% remain free primarily in the cytoplasm or are
located within signiﬁcantly smaller and so far uncharacterized
RNP particles19,20. Thus, it remained unclear whether or not
vtRNA1-1 exerts its anti-apoptotic characteristic on its own or as
part of the 13MDa vault complex. To address this question, we
speciﬁcally knocked down MVP, the principal protein component
of the vault complex, in the vtRNA1-1 overexpressing BL41 cell
line. To assess MVP assembled into genuine vault particles and
not free protein, the western blots were performed on the pellet
fraction of cell lysates that have passed a 100,000g centrifugation
step. While the vtRNA1-1 overexpressing cell line had clearly
elevated MVP levels compared with the parental BL41 cells as
judged by western blot analysis, MVP could be almost
quantitatively knocked down by the used shRNAs (Fig. 5a,
Supplementary Fig. 9). At the same time, the ectopically
expressed vtRNA1-1 levels remained high in the MVP
knockdown line (Fig. 5b). Importantly, when this MVP
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Figure 3 | Dose dependence of vtRNA1-1 levels on the impact of
apoptosis resistance. (a) Northern blot analyses demonstrate an shRNA-
mediated knockdown of vtRNA1-1 levels in BL41 cells of B50%. See also
Supplementary Fig. 6. (b) Annexin V staining revealed a reduced apoptosis
resistance in the vtRNA1-1 knockdown BL41 cell line after staurosporine
(Stau) treatment. The knockdown has been performed in two biological
replicates whereas the mean and standard deviations of four technical
replicates are shown. (c) Northern blot analysis showed an B60%
reduction of endogenous vtRNA1-1 levels in HeLa cells upon transfection of
an anti-sense oligonucleotide analogue (ASO). Administration of a control
oligonucleotide (ASO_ctr) strand had no effect. ( ) depict HeLa cells that
were treated as the transfected samples, but in the absence of any
oligonucleotides. Quantiﬁcations of band intensities are shown below the
blot and represent the mean and standard deviation of three independent
transfection experiments. The 5.8S rRNA served as internal loading control.
(d) Reduced endogenous vtRNA1-1 levels result in an increased
susceptibility to cell death in HeLa cells. The mean and standard deviations
of three independent transfection experiments are shown. (e,f) Analogous
to c and d, dose-dependent effects on apoptosis, resistance as a function of
vtRNA1-1 concentration were monitored in the human breast cancer cell
line HS578T. (g) In the presence of the NF-kB inhibitor (inh.) IKK VII,
northern blot analysis showed a decreased vtRNA1-1 expression level in
HeLa and HS578T cells. The 5.8S rRNA serves as internal loading control.
The endogenous levels of vtRNA1-1 in HeLa and HS578T cells was taken as
1.0 and compared with cells treated with a NF-kB inhibitor. In b, d and f,
signiﬁcant differences were determined using the two-tailed unpaired
Student’s t-test (***Po0.001, **Po0.01). pos., positive.
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knockdown cell line was subsequently infected with EBV for 72 h,
virus establishment rates remained high (Fig. 5c). In addition,
treatment with either staurosporine or etoposide did not alter the
fraction of apoptotic cells (Fig. 5d), which is in contrast to what
was observed after vtRNA1-1 knockdown (Fig. 3b). Hence, even
though the BL41 cells had basically no MVP expression and
consequently strongly reduced levels of genuine vault complexes,
vtRNA1-1 expression was high and sufﬁcient for triggering the
anti-apoptotic effect. This ﬁnding provides further evidence that
the anti-apoptotic effect of vtRNA1-1 is an intrinsic feature of this
ncRNA and is independent of the vault complex.
vtRNA1-1 affects the expression of central apoptosis regulators.
To investigate changes in cell death regulatory genes upon
vtRNA1-1 expression within the extrinsic or intrinsic apoptotic
pathways, a quantitative PCR array sampling 84 key marker genes
involved in programmed cell death was performed. BL41 as
well as BL41 cells overexpressing vtRNA1-1 were treated
with staurosporine for 4.5 h (a time point at which Annexin V
staining showed that BL41 started to commit to apoptosis) and
total RNA was subsequently isolated and used for the qPCR array.
By taking only apoptosis-related transcripts into consideration that
reproducibly displayed an at least 2-fold change in abundance,
resulted in a shortlist of 10 candidates (Fig. 6a; for the full list see
Supplementary Table 1). Among those, NOL3, also known as
‘apoptotic protein with CARD’ (ARC), showed the highest upre-
gulation upon vtRNA1-1 expression. This protein has been
reported to act anti-apoptotic34,35 in both the extrinsic as well as
the intrinsic pathway36. Another well-known apoptosis marker
identiﬁed in our screen was Bcl-xL (also referred to as BCL2-like
1), which was upregulated in vtRNA1-1 expressing cells by a factor
of 2.2 at the mRNA level (Fig. 6a). This pro-survival protein is
located at the outer mitochondrial membrane and is involved in
regulating the intrinsic apoptosis pathway but can also prevent
extrinsic cell death in several cell types37. Another family of
mRNAs that was deregulated upon vtRNA1-1 overexpression
included the TNF/TNFR superfamily members TNF, TNFSF10
(TRAIL), TNFSF8 (CD30-L), TNFRSF11B (OPG) and
TNFRSF10B (DR5, TRAIL-R2) (Fig. 6a). The latter result is
more difﬁcult to interpret in the context of apoptosis resistance, as
some members of the TNFR superfamily can mediate extrinsic cell
death as well as necroptosis but also participate in the
inﬂammatory response upon viral infection38.
The qPCR array and cell death data indicate that vtRNA1-1
expression affects cell survival by modulating both the intrinsic
(Fig. 2d, Fig. 3, Fig. 6a) as well as the extrinsic (Fig. 2e, Fig. 6a)
apoptosis pathways presumably by controlling the function of
common cell death regulators shared by these pathways. To
substantiate these ﬁndings, western blot analyses of selected
programmed cell death markers were performed. Indeed the anti-
apoptotic proteins Bcl-xL and ARC were upregulated in BL41
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cells expressing vtRNA1-1 upon staurosporine treatment, and
this correlated with a lack of caspase activation (Fig. 6b;
Supplementary Fig. 10). The vtRNA1-2 overexpression, on the
other hand, failed to inhibit processing of caspases, indicative for
their activation during apoptotic cell death.
To gain some mechanistic insight in vtRNA1-1-mediated
apoptosis resistance, we treated BL41 cells expressing vtRNA1-1
or vtRNA1-2 as well as the parental BL41 (which lacks vtRNA
expression) with the NF-kB agonist TNF. It became clear that in the
presence of vtRNA1-1, basal pathway activity was already increased
as indicated by the presence of phosphorylated IkB protein in
unstimulated cells. In particular, the kinetics and amplitude of IkB
phosphorylation, a key step preceding its degradation and
subsequent NF-kB nuclear translocation, was signiﬁcantly faster
and maintained longer when compared with the parental cells
expressing the vtRNA1-2 paralogue (Fig. 6c, Supplementary
Fig. 10). This phenomenon was reﬂected in higher mRNA levels
encoding for anti-apoptotic Bcl-xL that were not further augmented
by TNF treatment (Fig. 6c) but correlated with a notable increase in
Bcl-xL protein under baseline conditions (Fig. 6b).
In summary, we provide ﬁrst evidence that the non-coding
transcript vtRNA1-1 modulates the activity of both apoptosis
inducing pathways by increasing levels of Bcl-xL, at least in part,
by amplifying the baseline activity and potency of the NF-kB
signaling cascade.
Discussion
Despite the work of several research groups, the molecular
function of the vtRNA or the vault complex remains elusive39,40.
Here, we show that vtRNA1-1 is signiﬁcantly upregulated upon
expression of the EBV-encoded protein LMP1. Studying the
possible causal link between EBV infection and vtRNA1-1
upregulation, we revealed that vtRNA1-1 triggers general
apoptosis resistance in human Burkitt lymphoma cells, a
phenotype which is independent of the vault RNP complex.
Mutational analyses highlight the central domain of the vtRNA to
contributing to this phenotype.
These data demonstrate that vtRNA1-1 possesses a cellular
function in human cells, that is not connected to the vault
complex. This is, however, not the ﬁrst report that assigns a
biological function to a vtRNA not connected to the vault
complex in vivo. vtRNA1-1 was reported to serve as a precursor
for miRNA-like regulatory small RNAs, named svRNAs41, that
are able to dim CYP3A4 expression, a major drug metabolizing
enzyme. However, in the presented work, we do not observe any
smaller fragments of vtRNA1-1 on northern blots that might be
related to the svRNAs described by Persson et al.41 Furthermore
our mutational analyses point to the central domain of vtRNA1-1
as crucial determinant for the phenotype, while the previously
described svRNAs originate from the terminal stem-loop.
Another example for a vault complex-independent role of a
vtRNA is the association of vtRNA2-1 (also known as pre-miR-
886 or nc886) with the protein kinase R, which in consequence
suppresses tumour cell growth42. Taken together, these recent
reports and this study add to the growing body of evidence, that
vtRNAs are functional ncRNA molecules on their own and fulﬁl
cellular roles independently of the vault complex.
How is vtRNA1-1 expression linked to EBV infection and
apoptosis resistance? In general, viruses target the most effective
cellular switches to transform their hosts into virus factories43.
NcRNAs appear to be a good target for virus factors due to their
ability to rapidly regulate various critical cellular functions44. A
recent study demonstrated that a long ncRNA (lncRNA) was
speciﬁcally upregulated upon inﬂuenza A virus infection and that
the abundance of this lncRNA determines infection rates45. The
results by Winterling et al.45 and of the present work suggest that
different viruses target speciﬁc ncRNAs of their hosts. Thus,
particular ncRNAs, such as vtRNA1-1 in human B cells, can be
regarded as key cellular switches required to transform host cells
into viral factories. Our data suggest the following scenario: upon
EBV infection, the viral gene product LMP1 activates, via its
cytoplasmic C-terminal activator regions CTAR1 and CTAR2,
the NF-kB pathway leading to vtRNA1-1 upregulation. EBV-
triggered modulation of host transcription factors affecting
polymerase III promoters has already been observed before and
was suggested to stimulate cell growth46. LMP1 is known as the
major oncogene of the Epstein–Barr virus and several studies
suggest an anti-apoptotic and proliferative role of LMP1 (ref. 29).
In another study, it was recently shown that LMP1 expression in
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nasopharyngeal carcinoma and lymphoblastoid cell lines
elevates miRNA-21 levels, a known biomarker for chemo-
resistance, likely via the PI3K/Akt/FOXO3a pathway47. This, in
turn, downregulates the pro-apoptotic factors PDCD4 and Fas-L
possibly contributing to chemoresistance. In human B cell lines,
LMP1 functions differently and signals via the NF-kB pathway
(Fig. 1e,f, Supplementary Figs 3c,d and 11). Our study identiﬁes
vtRNA1-1 as a downstream target of LMP1 that on its own
appears sufﬁcient to increase NF-kB signalling (Figs 1 and 6c).
Among the affected NF-kB target genes is the key anti-apoptotic
protein Bcl-xL. The central role vtRNA1-1 plays in this scenario is
emphasized by the fact that Bcl-xL expression levels become
independent of ligand-dependent NF-kB activation in BL41 cells
ectopically expressing this ncRNA (Fig. 6c). These vtRNA1-1-
speciﬁc effects (especially on Bcl-xL levels), in turn, protect cells
from undergoing apoptosis. As a consequence, enhanced EBV
establishment (Fig. 2b) and cell proliferation rates were
observed (Supplementary Fig. 4a). The available data suggest
that vtRNA1-1 expression leads to the modulation of both the
extrinsic and the intrinsic apoptosis pathways (Figs 2d,e and
6a,b). Bcl-xL blocks both extrinsic as well as intrinsic apoptosis
upstream of mitochondrial outer membrane permeabilization by
preventing action of pro-apoptotic BH3-only proteins involved in
intrinsic apoptosis, for example, Bim, Puma, required for
staurosporine or etoposide killing48, as well as Bid, connecting
the mitochondrial pathway to death receptor-mediated apoptosis
in many cancer cells after caspase-8-mediated proteolysis37.
Likewise ARC has been demonstrated to inhibit both apoptotic
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pathways through a direct interaction with Bax and/or Fas49. This
is, to the best of our knowledge, the ﬁrst report of an ncRNA,
other than miRNAs, to directly affect both apoptotic pathways
and thus is able to modulate programmed cell death in human
cancer cells (Fig. 6d).
The vtRNAs received their names due to their association with
the 13 MDa vault complex7. With its 96 copies, the major vault
protein (MVP) is the dominant structural component of the vault
complex. Even though MVP was upregulated due to vtRNA1-1
overexpression in BL41 cells, knockdown of MVP levels did not
inﬂuence the anti-apoptotic effect of vtRNA1-1 (Fig. 5). This result
suggests that the MVP, and thus the genuine vault complex, is not
involved in the anti-apoptotic function of the vtRNA1-1. Recently
it was suggested that the MVP is responsible for prolonged cell
survival in human diploid ﬁbroblasts (HDFs) in an age-dependent
manner14. Senescent HDFs showed increased levels of MVP and
resisted apoptotic stimuli. As a marked upregulation of vtRNA1-1
was also observed in senescent HDFs due to apoptotic stress, it
cannot be ruled out that the observed apoptosis resistance
phenotype actually originates from the vtRNA and not from the
MVP. Also a more recent publication highlights the vtRNA1-1
levels and not the vault complex as a chemotherapy-resistance
mediator50, thus emphasizing that vtRNAs can accomplish cellular
functions even off the vault particle.
Although our study does not add to revealing the still elusive
cell biology of the vault complex, it shows that ‘free’ vtRNA1-1
has an anti-apoptotic effect in human cancer cell lines. In that
context, we note that 490% of vtRNA transcripts are not bound
to the vault complex in human cells, thus the RNA nomenclature
is misleading here since it implies a vault complex-related
function. Future work needs to characterize the speciﬁc
vtRNA1-1 RNP and the molecular mechanism that is responsible
for the observed anti-apoptotic phenotype. As summarized in
Fig. 6d, our data demonstrate a crucial role of vtRNA1-1, and
particularly its central domain, in conferring general apoptosis
resistance in different human cell lines (BL41, BL2, HS578T and
HeLa) by modulating the expression of anti-apoptotic proteins.
Methods
Cell culture. Burkitt lymphoma (BL) was initially described as tumour of young
children with a high EBV prevalence. BL cell lines have been established from
patients, including the EBV-negative cell lines BL2 and BL41 (refs. 51,52). IARC304
is an EBV-positive cell line derived from the same patient as BL2. The uniqueness of
these cell lines and the relationship between BL2 and IARC304 has been conﬁrmed
by the German Collection of Microorganisms and Cell Cultures (DSMZ).The EBV-
negative Burkitt lymphoma cell lines BL41, BL2, kindly provided by F. Gra¨sser;
Homburg/Saar, Germany and IARC304 were cultured in RPMI 1640 supplemented
with 10% fetal calf serum, 292mgml 1 L-glutamin and antibiotics (100U
penicillin ml 1 and 100mg streptomycin ml 1). After successful lentiviral
transduction, positively infected cells were selected by treating them with 1mgml 1
puromycin (or 200mgml 1 G418) for at least 1 week. After B7 days of recovery
time, the concentration of the antibiotic was raised to 2mgml 1 puromycin or
800mgml 1 G418, respectively. For experiments addressing NF-kB signaling,
LMP1-expressing BL2 cells and HS578T cells were treated with 10mM IKK Inhibitor
VII (Calbiochem) for 18 h. HeLa cells were treated with 20mM IKK Inhibitor VII
(Calbiochem) for 18 h. Cells were collected by centrifugation, total RNA was
prepared and vtRNA1-1 expression was analysed by northern blotting (see below).
HeLa, HS578T and HEK 293 T cells (kindly provided by R. Berger, Department of
Gynecology, Medical University Innsbruck, Austria) were grown in DMEM medium
supplemented with 10% fetal calf serum, 292mgml 1 L-glutamine and antibiotics
(100U penicillin ml 1 and 100mg streptomycin ml 1).
Overexpression of EBV-encoded proteins. EBV-encoded proteins were ampli-
ﬁed from plasmid-cloning vectors with speciﬁc PCR primers (Supplementary
Table 2). The various LMP1 mutants are described in ref. 53. For the generation of
the complete Gateway recombination sites, a further PCR was necessary
(Supplementary Table2; AttB1 and AttB2). According to the Gateway Cloning
Technology (Invitrogen), PCR products were recombined with a pDONOR-207
vector and subsequently sequence-veriﬁed entry clones were recombined with
the lentiviral destination vector pHR-PGK-dest–SFFV-Puro. In the case of
LMP2b and EBNA-LP, entry clones containing the CMV (for LMP2b) or the SV40
(for EBNA-LP) promoters were recombined with the lentiviral destination vector
pHR-dest-SFFV-Puro.
Lentiviral transduction. Lentiviral particles were generated in human HEK 293 T
cells, which were transiently transfected with lentiviral plasmids containing cDNAs
coding for all gene products mentioned in the text, together with the packaging
plasmids pSPAX and the envelope plasmid pVSV-G. After 48 h and 72 h lentiviral
supernatant was collected, sterile ﬁltered (Whatman Puradisc FP30, 0.2 mM) and
supplemented with polybrene (Millipore) to a ﬁnal concentration of 4 mgml 1 and
added to the target cells overnight.
Northern blot. Ten micrograms of total RNA (prepared with TRI Reagent (Sigma
Aldrich) ofB10 millions of cells according to the manufacturer’s protocol) isolated
either from HeLa, HS578T cells or from the B cell lines BL41 and BL2 and deri-
vatives thereof were separated on 8% denaturing polyacrylamide gels (7M urea,
1 TBE buffer), transferred onto nylon membranes, UV crosslinked and probed
with 50-[32P] end-labelled antisense DNA probes (Supplementary Table 2) as
described54. Northern blot signals were visualized by autoradiography and
quantiﬁed using ImageJ version 1.46. All quantiﬁed northern blot signals were
normalized to the band intensities of the 5.8S or 5S rRNA loading controls.
Western blot. Cells (except for MVP detection, see below) were solubilized with
2 La¨mmli buffer (4% SDS, 20% Glycerol, 125mM Tris/HCl pH 6.8, 200mM
b-mercaptoethanol and bromphenol blue) or with NP40 lysis buffer (150mM
NaCl, 50mM Hepes pH 7.5, 5mM EDTA, 0.1% NP40, 1mM PMSF). The same
amount of protein content for each sample (determined by cell counting) was
resolved by a 4–20% or 8–15% Tris/Glycin gradient SDS polyacrylamide gel,
transferred onto a nitrocellulose membrane (Amersham Biosciences) and blocked
with TBS containing Tween-20 in 5% nonfat dry milk overnight. The membranes
were incubated with the primary antibodies at room temperature for 1 h. Horse-
radish peroxidase conjugated secondary antibodies or IRDye-conjugated secondary
antibodies (LI-COR) were added for 1 h at room temperature. Immune complexes
were visualized using an enhanced chemiluminescence (ECL) reagent, or ECL-
femto (Pierce Thermo scientiﬁc) or were visualized with the Odyssey imaging
system according to the manufacturer’s instructions. The following antibodies and
dilutions for western blotting were used: mouse anti-MVP 1:500 (Santa Cruz);
mouse anti-HA tag (16B12, Covance) 1:500; rabbit anti-FLAG 1:5,000 (F7425,
Sigma), Histidine Tag (6xHis) mouse anti-histidine Tag monoclonal Antibody
(clone 3D5, Life Technologies); rat anti-EBNA1 1:50 (ref. 55); rat anti-EBNA2
(1:20, ref. 56); mouse anti-EBV 1:1,000 (Dianova),rabbit anti–PDCD4 1:1,000
(D29C6, Cell Signaling); rabbit anti-cleaved caspase-3 1:1,000 (5A1E, Cell
Signaling); rabbit anti-cleaved caspase-9 1:1,000 (D2D4, Cell Signaling); mouse
anti-cleaved caspase-8 1:1,000 (11G10, Cell Signaling); goat anti-mouse IgG HRP
Conjugate 1:10,000 (Invitrogen); goat anti–rabbit IgG HRP Conjugate 1:15,000
(Pierce); anti-ribosomal protein L9 (Santa Cruz); rabbit anti-Bcl-xL 1:1,000
(54H6, Cell Signaling), rabbit anti-ARC 1:1,000 (sc-11435, Santa Cruz); rabbit
anti-GAPDH 1:1,000 (14C10, Cell Signaling), rabbit anti-NFkB p65 (Santa Cruz,
sc-372) 1: 500, rabbit anti Phospho-IkBa (Ser32) 1:250 (14D4, Cell Signaling),
mouse anti-HSP 90 1:1,000 (AC-16, Santa Cruz).
For MVP detection, a concentration step namely a P100 preparation was
necessary. 5 106 cells were washed with phosphate-buffered saline (PBS), pelleted
by centrifugation (450g for 5min), snap frozen to disrupt the cell membranes,
dissolved in 1ml of buffer A complete (50mM Tris-HCl pH7.4, 1.5mM MgCl2,
75mM NaCl, 1% Triton X-100, 1mM DTT, 1mM PMSF, 0.1% Nonidet–P40,
protease inhibitor cocktail complete Mini EDTA-free 1 (Roche)) followed by
incubation for 10min on ice and subsequent centrifugation at 20,000g at 4 C for
20min. The resulting supernatant was again centrifuged in an ultracentrifuge for
1 h at 100,000g (TLA-55 rotor). The supernatant was discarded and the pellet,
containing vault complexes, was dissolved in 60 ml of buffer A complete. Then,
60 ml of 2 Laemmli sample buffer (without b-mercaptoethanol but including 7M
urea) was added followed by vigorous vortexing, sonication (for 5 sec at 200W with
a BRANSON SONIFIER 150) and supplemented with 50mM b-mercaptoethanol
(ﬁnal concentration).
Real-time PCR. Total RNA was isolated from different BL2 and BL41 cell lines
with TRI Reagent (Sigma Aldrich) according to the manufacturer’s protocol. An
amount of 2.5 mg of total RNA was reverse transcribed to cDNA using Superscript
II (Invitrogen Karlsruhe) and random hexamer primers following the manu-
facturer’s instructions. The expression of vtRNA1-1 and TATA box binding pro-
tein (TBP) mRNA was investigated by real-time PCR using Taq Man primers and
probes (ABI). PCR was performed using Rotor Gene 6200 real-time thermocycler
with the following thermal conditions: 50 C for 2min, 95 C for 10min, 40 cycles
each of 95 for 15 s and 60 C for 1min. Reactions were performed in triplicates.
For the NF-kB target genes (Bcl-xL, IL6, c-Flip) the Brilliant III ultra-fast SYBR
Green qPCR master mix (Agilent Technologies) was used on the Rotor gene 6200
thermocycler with the following conditions: 95 C for 3min, 40 cycles each of 95 C
for 10 s and 60 C for 15 s. Quantiﬁcation was calculated using the DDCT method
with TBP mRNA as endogenous control. The used primers are listed in
Supplementary Table 2.
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For transcriptionally regulated target search a RT2 Proﬁler PCR Array (Qiagen)
was performed. A total 2.5 106 BL41 as well as BL41 vtRNA1-1 expressing cells
were incubated with staurosporine for 4.5 h. The cells were pelleted by
centrifugation (400g, 5min) and RNA was extracted according to the TRI-Reagent
(Sigma Aldrich) protocol. A total 8 mg of the extracted RNA was treated with 1U of
RQ DNase (Promega) in 1RQ DNase buffer for 30min at 37 C to get rid of
residual DNA. Afterwards the RNA was puriﬁed with the RNeasy Mini Kit
according to Qiagen’s protocol and reverse transcribed into cDNA using the RT2
First Strand Kit as described in the RT2 Proﬁler PCR Array Handbook (12/2012).
The array was run on an ABI ViiA 7 cycler. Cycling conditions as well as data
analysis was performed according to the manufacturer’s recommendations.
Expression levels of the different genes were normalized to the average of ﬁve
different housekeeping genes (as described in the RT2 Proﬁler PCR Array
Handbook) and ‘fold changes’ were calculated using the comparative 2 (DDCT)
method where BL41 served as calibrator and BL41 expressing vtRNA1-1 as target.
Chromatin immunoprecipitation assay. A total 1 107 BL2 cells were exposed to
1% formaldehyde at room temperature for 10min to obtain protein-DNA cross
linking. After soniﬁcation for 15min (40% output, 30 sec on/off), the lysates were
centrifuged at 13,000g, 15min, 4 C. The supernatants were diluted to 250mgml 1
in ChiP dilution buffer (25mM HEPES/pH 7.5, 140mM NaCl, 1mM EDTA/pH
8.0, 0.5mM EGTA/pH 8.0). Five microgram of anti-NF-kB p65 antibody
(C20, sc-372X; Santa Cruz Biotechnology) or 5 mg of control IgG were coupled
to protein A magnet beads (Dynabeads; Life Technology) for 8 h at 4 C.
Subsequently, the bead-coupled antibodies were washed three times in 1 PBS,
0.5% bovine serum albumin (BSA) and incubated with 250mgml 1 soniﬁed
chromatin overnight at 4 C. The protein-DNA-antibody complexes were washed
ﬁve times with cold wash buffer (50mM HEPES-KOH/pH7.5, 500mM LiCl, 1mM
EDTA, 1% NP-40, 0.7% Na-deoxycholate), once with TEþ 50mM NaCl and
resuspended in elution buffer (50mM Tris-HCl/pH 8.0, 10mM EDTA, 1% SDS).
Crosslinks were reversed in elution buffer for 9 h at 65 C. After RNase A and
proteinase K treatment, the DNA was puriﬁed by phenol/chloroform extraction
and ethanol precipitated. Quantitative real-time PCR (3min 95 C, 40 cycles each
10 s 95 C and 15 s 50 C) was performed with Brilliant III ultra-fast SYBR Green
qPCR master mix (Agilent Technologies) to amplify a distinct region of the
vtRNA1-1 promoter and of the vtRNA1-2 promoter region. Primer sequences are
listed in Supplementary Table 2. Quantiﬁcation was calculated as fold-enrichment,
representing the ChiP signal as x-fold increase in signal to the no-antibody (mock
IgG) signal.
Annexin V staining. After treatment with 50 nM (f.c.) staurosporine for 24 h,
850 nM (f.c.) etoposide for 24 h, 500 ng Fas antibody clone CH11 (Millipore) for
48 h, or 2089 EBV (at a multiplicity of infection of 5) for 72 h, B2 105 of
suspended cells were collected by centrifugation (450g, 5min), then washed once
with ice-cold PBS, again centrifuged and ﬁnally dissolved in 100 ml 1 Annexin
binding buffer (0.01M Hepes pH 7.4, 0.15M NaCl, 2.5mM CaCl2). Annexin V PE
(2.5ml) was added to the cells, which were then incubated for 15min in the dark.
The samples were analysed by ﬂow cytometry within 1 h on a FACSCalibur
(Becton Dickinson, Schwechat, Austria) and gated on the basis of forward versus
side scatter for size. The number of apoptotic cells was determined by recording the
FL-2 channel.
MVP knockdown. A constitutive MVP knockdown cell line was constructed using
a lentiviral shRNA expression vector containing a neomycin resistance gene for
selection of positive clones. The target sequences for the performed knockdown
was the following: 50-CCCATACCACTATATCCATGT-30 . A plasmid expressing
the shRNA targeting MVP was generated by annealing phosphorylated oligonu-
cleotides, followed by ligation into a BglII/HindIII digested pENTR-THT vector.
Thereafter, a sequence-veriﬁed clone was used for L/R recombination into the
ﬁnal lentiviral destination vector thereby generating pHR-THT-MVP shRNA-
SFFV-Neo. The whole shDNA sequence for MVP knockdown is listed in
Supplementary Table 2.
Vault RNA expression. vtRNA1-1 with its upstream and downstream regulatory
regions was ampliﬁed from genomic DNA of BL2/B95.8 cells within two PCR
reactions. The speciﬁc ampliﬁcation of the region of vtRNA1-1 was done using a
nested PCR with the 50hvg1-big and 3’hvg1-big primers. The product of the nested
PCR (4.128 kb) was puriﬁed via agarose gel electrophoresis and it served as a
template for another PCR resulting in a 644-nt long PCR product (hvg1-2 as well
as hvg 1-4 primer containing an EcoRI and BamHI restriction site, respectively and
all necessary regulatory regions in the vtRNA1-1 gene surrounding). The PCR
product was then agarose gel puriﬁed, digested with EcoRI and BamHI restriction
enzymes and cloned into a promoterless entry vector. Using Invitrogen’s Gateway
recombination system, a sequence-veriﬁed entry clone was recombined with the
lentiviral destination vector pHR-dest-SFFV-Puro resulting in pHR-vtRNA1-
1_locus-SFFV-Puro. The vtRNA1-2 as well as the vtRNA1-3 gene locus encom-
passing upstream and downstream regulatory regions was chemically synthesized
(Life Technologies, Geneart), digested with XhoI and EcoRI and cloned into
pENTR-U243. Five different vtRNA1-1 mutations were generated via overlapping
PCR. The listed primers (Supplementary Table 2) were used to generate vtRNA1-1
mutants M1 to M5 from the pENTR-U243-vtRNA1-1 plasmid.
vtRNA1-1 knockdown. A constitutive vtRNA1-1 knockdown cell line was con-
structed analogous to the described MVP knockdown cell lines (see above). The
target sequence on vtRNA1-1 was the following: 50-GGCUGGCUUUAGCU-
CAGCG-30 . The whole shDNA sequence for the vtRNA1-1 knockdown is listed in
Supplementary Table 2.
To reduce endogenous vtRNA1-1 levels in HeLa cells or HS578T cells,
chemically modiﬁed chimeric ASOs were used. Therefore 5 106 HeLa cells were
transiently transfected (jetPEI, Polyplus) with 1 mM ASOs (Exiqon), directed
against vtRNA1-1 or as a control against vtRNA1-2. After 24 h, cells were collected
by centrifugation (450g, 5min), stained with Annexin V and analysed by ﬂow
cytometry (as described above). ASOs were designed as RNA/DNA/RNA chimeric
oligonucleotides with a phosphorothioate backbone. Ten central
deoxyribonucleotides are ﬂanked by ﬁve 20-O-methyl modiﬁed ribonucleotides on
both sides (Supplementary Table 2).
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